S&P 500   4,981.80 (+0.13%)
DOW   38,612.24 (+0.13%)
QQQ   425.61 (-0.40%)
AAPL   182.32 (+0.42%)
MSFT   402.18 (-0.15%)
META   468.03 (-0.68%)
GOOGL   142.55 (+1.01%)
AMZN   168.59 (+0.90%)
TSLA   194.77 (+0.52%)
NVDA   674.72 (-2.85%)
NIO   5.97 (+0.17%)
AMD   164.29 (-0.84%)
BABA   75.58 (+3.34%)
T   17.01 (+0.59%)
F   12.15 (-0.82%)
MU   81.49 (+0.97%)
CGC   3.44 (-2.82%)
GE   149.08 (+0.31%)
DIS   107.68 (-1.61%)
AMC   4.57 (-1.93%)
PFE   27.67 (+0.29%)
PYPL   57.48 (-1.96%)
XOM   104.86 (+2.05%)
S&P 500   4,981.80 (+0.13%)
DOW   38,612.24 (+0.13%)
QQQ   425.61 (-0.40%)
AAPL   182.32 (+0.42%)
MSFT   402.18 (-0.15%)
META   468.03 (-0.68%)
GOOGL   142.55 (+1.01%)
AMZN   168.59 (+0.90%)
TSLA   194.77 (+0.52%)
NVDA   674.72 (-2.85%)
NIO   5.97 (+0.17%)
AMD   164.29 (-0.84%)
BABA   75.58 (+3.34%)
T   17.01 (+0.59%)
F   12.15 (-0.82%)
MU   81.49 (+0.97%)
CGC   3.44 (-2.82%)
GE   149.08 (+0.31%)
DIS   107.68 (-1.61%)
AMC   4.57 (-1.93%)
PFE   27.67 (+0.29%)
PYPL   57.48 (-1.96%)
XOM   104.86 (+2.05%)
S&P 500   4,981.80 (+0.13%)
DOW   38,612.24 (+0.13%)
QQQ   425.61 (-0.40%)
AAPL   182.32 (+0.42%)
MSFT   402.18 (-0.15%)
META   468.03 (-0.68%)
GOOGL   142.55 (+1.01%)
AMZN   168.59 (+0.90%)
TSLA   194.77 (+0.52%)
NVDA   674.72 (-2.85%)
NIO   5.97 (+0.17%)
AMD   164.29 (-0.84%)
BABA   75.58 (+3.34%)
T   17.01 (+0.59%)
F   12.15 (-0.82%)
MU   81.49 (+0.97%)
CGC   3.44 (-2.82%)
GE   149.08 (+0.31%)
DIS   107.68 (-1.61%)
AMC   4.57 (-1.93%)
PFE   27.67 (+0.29%)
PYPL   57.48 (-1.96%)
XOM   104.86 (+2.05%)
S&P 500   4,981.80 (+0.13%)
DOW   38,612.24 (+0.13%)
QQQ   425.61 (-0.40%)
AAPL   182.32 (+0.42%)
MSFT   402.18 (-0.15%)
META   468.03 (-0.68%)
GOOGL   142.55 (+1.01%)
AMZN   168.59 (+0.90%)
TSLA   194.77 (+0.52%)
NVDA   674.72 (-2.85%)
NIO   5.97 (+0.17%)
AMD   164.29 (-0.84%)
BABA   75.58 (+3.34%)
T   17.01 (+0.59%)
F   12.15 (-0.82%)
MU   81.49 (+0.97%)
CGC   3.44 (-2.82%)
GE   149.08 (+0.31%)
DIS   107.68 (-1.61%)
AMC   4.57 (-1.93%)
PFE   27.67 (+0.29%)
PYPL   57.48 (-1.96%)
XOM   104.86 (+2.05%)

Creative Medical Technology (CELZ) Competitors

$4.22
-0.09 (-2.09%)
(As of 02/21/2024 ET)

CELZ vs. FRTX, TCON, TTNP, GENE, FNCH, PALI, EIGR, BCDA, ONVO, and ELOX

Should you be buying Creative Medical Technology stock or one of its competitors? The main competitors of Creative Medical Technology include Fresh Tracks Therapeutics (FRTX), TRACON Pharmaceuticals (TCON), Titan Pharmaceuticals (TTNP), Genetic Technologies (GENE), Finch Therapeutics Group (FNCH), Palisade Bio (PALI), Eiger BioPharmaceuticals (EIGR), BioCardia (BCDA), Organovo (ONVO), and Eloxx Pharmaceuticals (ELOX). These companies are all part of the "biological products, except diagnostic" industry.

Creative Medical Technology vs.

Creative Medical Technology (NASDAQ:CELZ) and Fresh Tracks Therapeutics (NASDAQ:FRTX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, valuation, community ranking, institutional ownership, media sentiment and risk.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Creative Medical Technology
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
Fresh Tracks Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

In the previous week, Fresh Tracks Therapeutics had 1 more articles in the media than Creative Medical Technology. MarketBeat recorded 2 mentions for Fresh Tracks Therapeutics and 1 mentions for Creative Medical Technology. Fresh Tracks Therapeutics' average media sentiment score of 1.25 beat Creative Medical Technology's score of 0.00 indicating that Fresh Tracks Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Creative Medical Technology
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Fresh Tracks Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Creative Medical Technology has higher earnings, but lower revenue than Fresh Tracks Therapeutics. Creative Medical Technology is trading at a lower price-to-earnings ratio than Fresh Tracks Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Creative Medical Technology$90K65.93-$10.14M-$7.80-0.55
Fresh Tracks Therapeutics$6.94M0.79-$21.10M-$2.71-0.34

Creative Medical Technology has a beta of 2.2, indicating that its share price is 120% more volatile than the S&P 500. Comparatively, Fresh Tracks Therapeutics has a beta of 0.4, indicating that its share price is 60% less volatile than the S&P 500.

Creative Medical Technology has a net margin of 0.00% compared to Fresh Tracks Therapeutics' net margin of -91.29%. Creative Medical Technology's return on equity of -69.54% beat Fresh Tracks Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Creative Medical TechnologyN/A -69.54% -64.36%
Fresh Tracks Therapeutics -91.29%-102.00%-81.35%

1.4% of Creative Medical Technology shares are owned by institutional investors. Comparatively, 1.7% of Fresh Tracks Therapeutics shares are owned by institutional investors. 3.3% of Creative Medical Technology shares are owned by company insiders. Comparatively, 0.2% of Fresh Tracks Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Creative Medical Technology received 71 more outperform votes than Fresh Tracks Therapeutics when rated by MarketBeat users. Likewise, 68.93% of users gave Creative Medical Technology an outperform vote while only 0.00% of users gave Fresh Tracks Therapeutics an outperform vote.

CompanyUnderperformOutperform
Creative Medical TechnologyOutperform Votes
71
68.93%
Underperform Votes
32
31.07%
Fresh Tracks TherapeuticsOutperform Votes
No Votes
Underperform Votes
1
100.00%

Summary

Creative Medical Technology beats Fresh Tracks Therapeutics on 9 of the 15 factors compared between the two stocks.


Get Creative Medical Technology News Delivered to You Automatically

Sign up to receive the latest news and ratings for CELZ and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CELZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CELZ vs. The Competition

MetricCreative Medical TechnologyBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$5.93M$2.67B$4.92B$7.33B
Dividend YieldN/A2.40%2.92%3.85%
P/E Ratio-0.554.52101.7616.07
Price / Sales65.93277.833,005.5357.75
Price / CashN/A22.1689.9854.00
Price / Book0.383.854.294.57
Net Income-$10.14M$60.27M$111.86M$206.97M
7 Day Performance-1.15%2.49%1.63%0.67%
1 Month Performance1.65%11.48%7.23%4.51%
1 Year Performance-42.79%5.03%7.20%3.77%

Creative Medical Technology Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
FRTX
Fresh Tracks Therapeutics
0 of 5 stars
$0.99
+1.0%
N/A-54.0%$5.91M$6.94M-0.3713News Coverage
TCON
TRACON Pharmaceuticals
0.9456 of 5 stars
$0.19
-4.0%
$4.33
+2,206.2%
-89.2%$5.85M$9M-0.3218Analyst Report
Gap Down
TTNP
Titan Pharmaceuticals
0 of 5 stars
$7.19
-1.0%
N/A-58.9%$5.39M$560,000.000.004Analyst Report
Gap Down
GENE
Genetic Technologies
0 of 5 stars
$1.93
+1.4%
N/A-71.0%$7.42M$5.85M0.0060Gap Up
FNCH
Finch Therapeutics Group
0.6287 of 5 stars
$2.55
-1.5%
$210.00
+8,135.3%
-80.1%$4.11M$860,000.00-0.0418Positive News
PALI
Palisade Bio
2.9763 of 5 stars
$0.44
-2.2%
$8.75
+1,888.6%
-81.0%$4.08MN/A0.0012Gap Up
EIGR
Eiger BioPharmaceuticals
4.1631 of 5 stars
$5.76
-3.4%
$120.00
+1,983.3%
-91.5%$8.53M$13.48M-0.1056Analyst Report
News Coverage
BCDA
BioCardia
2.2193 of 5 stars
$0.41
+2.0%
$4.00
+875.6%
-81.1%$8.86M$1.35M-0.6630Gap Up
ONVO
Organovo
0 of 5 stars
$0.90
-10.0%
N/A-64.3%$9.04M$370,000.00-0.4115Gap Up
ELOX
Eloxx Pharmaceuticals
1.0824 of 5 stars
$0.75
-9.6%
$55.00
+7,233.3%
-80.4%$2.36MN/A-0.0818Gap Up

Related Companies and Tools

This page (NASDAQ:CELZ) was last updated on 2/21/2024 by MarketBeat.com Staff